Tapre Timine
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the use of R21 malaria vaccine developed by scientists at Oxford University in Nigeria.
Mojisola Adeyeye, director-general of NAFDAC made the announcement at a press briefing on Monday.
Adeyeye said:
ATTENTION: Click “HERE” to join our WhatsApp group and receive News updates directly on your WhatsApp!
“The National Agency for Food and Drug Administration and Control (NAFDAC) in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 is granting registration approval for R21 malaria vaccine.
“The vaccine is indicated for prevention of clinical malaria in children from five months to 36 months of age. The storage temperature of the vaccine is 2-8 °C.
“Overall, the R21 malaria vaccine dossier complied substantially with best international standards with which the dossier was benched-marked as mentioned above. The joint review committee concluded that the data on the R21 malaria vaccine were robust and met criteria for efficacy, safety, and quality.
“It was also adjudged that the vaccine’s known and potential benefits outweigh its known and potential risks, thereby supporting the manufacturer’s recommended use.
“A provisional approval of the R21 malaria vaccine was recommended and this shall be done in line with the WHO’s malaria vaccine implementation guideline.
“While granting the approval, the agency has also communicated the need for expansion of the clinical trial conducted to include a phase 4 clinical trial/pharmacovigilance study to be carried out in Nigeria.
“The brief on the approval of the R21 Malaria vaccine has been communicated to the minister of health and national primary health care development agency for appropriate actions toward immunisation in the respective population.”
Details shortly…
